Zepbound, the tirzepatide product and a dual GIP/GLP-1 agonist, received FDA weight-loss approval in November 2023, two years after Wegovy's November 2021 clearance
Before we knew it, every other commercial on our TVs was a telehealth commercial promoting their new, shiny platform to help with mental health, hair loss, erectile dysfunction, and you guessed itweight loss
Some researchers explore combinations with tesamorelin or cagrilintide , though interaction data is limited
doi:10.1519/JSC.0b013e31817d48d9
Important side effects that warrant immediate attention by a doctor include persistent vomiting, diarrhea and/or abdominal pain
But if time or lack of cooking skills is your biggest barrier, they are worth the investment